Ivacaftor API Suppliers & Bulk Manufacturers
Available Forms: API (drug substance)
Available Strengths: USP grade or in-house specification
Reference Brands: Kalydeco, Orkambi, Symdeko, Trikafta, Kaftrio
Category: Active Pharmaceutical Ingredient
Ivacaftor is a CFTR potentiator used alone and in combination cystic fibrosis products. It is sourced by formulators, CDMOs and R&D teams preparing future generic filings.
Manufacture or export Ivacaftor API? List it or send an offer →
Product Description:
Ivacaftor is a CFTR potentiator: it increases the time the chloride channel stays open at the cell surface, improving salt and water movement in the airways and other organs. It is approved for cystic fibrosis in patients aged 1 month and older (US) who carry at least one CFTR mutation responsive to ivacaftor, and it is also part of fixed-dose combinations with other CFTR modulators (reference brand: Kalydeco, Orkambi, Symdeko, Trikafta, Kaftrio).
Specification at a glance
| Traded form | Free base; white to off-white powder, practically insoluble in water. Marketed products use an amorphous solid dispersion made from the API |
|---|---|
| CAS number | 873054-44-5 |
| Molecular formula | C24H28N2O3 |
| Molecular weight | 392.49 g/mol |
| Pharmacopoeia | No Ph. Eur., BP or JP monograph found. Ivacaftor was listed by USP for monograph development and its current USP status is unverified; otherwise supplied to an in-house specification. |
Regulatory files and timing
The FDA list of Drug Master Files (third quarter 2026) shows 15 active Type II API DMFs for this molecule. There is a fair choice of sources, so compare documents and impurity profiles, not just price. For Europe, ask whether the supplier holds a CEP or an EU ASMF and, for imports into the EU, a written confirmation.
Generic or biosimilar entry. United States: Patent expiry; entry not confirmed (2028). European Union: Patent expiry; entry not confirmed (2027).
Handling and quality points
Ivacaftor is practically insoluble in water, which is why finished products rely on a spray-dried amorphous dispersion, so the API's solid form, particle size and residual solvents affect how it processes. The molecule forms several polymorphs and solvates, so agree the form and its XRPD fingerprint with the supplier. It is not a high-potency compound in the usual sense, but standard industrial hygiene and dust control apply.
Send an API enquiry All specialty APIs
Brand names are trademarks of their respective owners and identify the reference medicine only. Information is general and was checked in October 2026; confirm specifications and filings with the supplier before purchase.
Ivacaftor API — third party manufacturing & bulk supply
Ivacaftor API is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Ivacaftor API is supplied as API (drug substance) — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Ivacaftor API listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Ivacaftor API →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Buyers normally request the GMP certificate, a US DMF letter of access or EU ASMF, a CoA with XRPD, residual solvents and related substances, and stability data. A nitrosamine risk assessment and an ICH M7 assessment of synthesis impurities are standard additions. If you plan a combination product, ask about compatibility data with the partner modulators.
Yes, though less for the final product than for processing. The form and its solvent content affect solubility in the spray-drying solvent, impurity carry-over and the stability of the stored API. Specify a form, ask for XRPD and thermal data, and check that residual solvents meet ICH Q3C limits after drying.
Yes. PharmaTradz links licensed manufacturers, CDMOs and R&D teams with GMP-compliant ivacaftor makers. We check documents before introducing anyone, and your details remain private until both parties agree.
Related Products
Abaloparatide API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Tymlos, Eladynos
View DetailsRavtansine (DM4) API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Elahere
View DetailsDalbavancin Hydrochloride API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Dalvance, Xydalba
View DetailsCariprazine Hydrochloride API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Vraylar, Reagila
View DetailsPasireotide API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Signifor, Signifor LAR
View DetailsVenetoclax API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Venclexta, Venclyxto
View DetailsEncorafenib API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Braftovi
View DetailsOzanimod Hydrochloride API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Zeposia
View DetailsUsually answered within 48 hours | GMP documents shared before you commit